The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

This manual helps clinicians design and implement intensive outpatient treatment programs for people living with substance use disorder conditions. It discusses cultural competence and approaches, use of 12-step programs, cognitive behavioral therapy, and therapeutic communities.

This manual provides clinical practice guidelines for using medications in the medication-assisted treatment of alcohol use disorder. It offers guidance on prescribing acamprosate, disulfiram, oral naltrexone, and extended-release injectable naltrexone. The manual also discusses patient management. Access the literature review.

This manual provides guidelines for administrators on addressing issues in outpatient treatment for alcohol and substance misuse. It discusses cultural competence, management and strategic collaborations, human resources, financing, and performance and outcomes improvement.